PriceTargets.com logo

Aclaris Therapeutics - ACRS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $9.75
  • Forecasted Upside: 223.92%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$3.01 As of 12/4/2025 05:00 PM ET
▲ +0.23 (8.27%)

This chart shows the closing price for ACRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aclaris Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACRS

Analyst Price Target is $9.75
▲ +223.92% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Aclaris Therapeutics in the last 3 months. The average price target is $9.75, with a high forecast of $16.00 and a low forecast of $6.00. The average price target represents a 223.92% upside from the last price of $3.01.

This chart shows the closing price for ACRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 polled investment analysts is to moderate buy stock in Aclaris Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/17/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/11/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/5/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/20/2025HC WainwrightReiterated RatingBuy ➝ Buy$16.00
10/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/10/2025Piper SandlerInitiated CoverageOverweight$6.00
6/25/2025HC WainwrightReiterated RatingBuy ➝ Buy$16.00
6/23/2025WedbushReiterated RatingOutperform$8.00
5/28/2025WedbushInitiated CoverageOutperform$8.00
5/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $16.00
5/9/2025ScotiabankLower TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.00
3/18/2025Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight
3/7/2025ScotiabankInitiated CoverageSector Outperform$15.00
3/4/2025Cantor FitzgeraldUpgradeStrong-Buy
1/30/2025Cantor FitzgeraldUpgradeStrong-Buy
12/23/2024HC WainwrightUpgradeNeutral ➝ Buy$20.00 ➝ $20.00
11/20/2024Cantor FitzgeraldUpgradeNeutral ➝ Overweight
11/19/2024Leerink PartnrsUpgradeHold ➝ Strong-Buy
11/19/2024Leerink PartnersUpgradeMarket Perform ➝ Outperform$2.00 ➝ $7.00
11/19/2024Jefferies Financial GroupUpgradeHold ➝ Buy$2.00 ➝ $7.00
11/19/2024BTIG ResearchUpgradeNeutral ➝ Buy$8.00
11/18/2024Piper SandlerUpgradeNeutral ➝ Overweight$3.00 ➝ $13.00
9/17/2024HC WainwrightReiterated RatingNeutral
8/19/2024HC WainwrightReiterated RatingNeutral
7/22/2024HC WainwrightReiterated RatingNeutral
1/22/2024HC WainwrightDowngradeBuy ➝ Neutral
1/12/2024Cantor FitzgeraldReiterated RatingNeutral
1/11/2024BTIG ResearchReiterated RatingBuy ➝ Neutral
12/29/2023HC WainwrightReiterated RatingBuy ➝ Buy$9.00
12/18/2023Cantor FitzgeraldReiterated RatingNeutral
11/14/2023HC WainwrightLower TargetBuy ➝ Buy$43.00 ➝ $9.00
11/14/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral
11/13/2023Leerink PartnrsDowngradeOutperform ➝ Market Perform
11/13/2023Stifel NicolausReiterated RatingBuy ➝ Hold
11/13/2023William BlairDowngradeOutperform ➝ Market Perform
10/9/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$38.00
10/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$43.00
10/3/2023Evercore ISIInitiated CoverageOutperform$22.00
9/19/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$38.00
9/19/2023HC WainwrightReiterated RatingBuy ➝ Buy$43.00
9/14/2023Stifel NicolausBoost TargetBuy ➝ Buy$16.00 ➝ $20.00
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$43.00
3/7/2023The Goldman Sachs GroupLower TargetBuy$25.00 ➝ $21.00
3/7/2023BTIG ResearchLower TargetBuy$32.00 ➝ $29.00
3/7/2023HC WainwrightLower TargetBuy$50.00 ➝ $43.00
2/24/2023HC WainwrightReiterated RatingBuy$50.00
2/7/2023Cantor FitzgeraldReiterated RatingOverweight$38.00
12/13/2022Stifel NicolausInitiated CoverageBuy$29.00
12/1/2022The Goldman Sachs GroupInitiated CoverageBuy$25.00
11/8/2022Leerink PartnersReiterated RatingOutperform
10/6/2022BTIG ResearchInitiated CoverageBuy$32.00
8/1/2022Cantor FitzgeraldReiterated RatingOverweight
5/11/2022William BlairReiterated RatingOutperform
2/25/2022Cantor FitzgeraldReiterated RatingOverweight
12/20/2021HC WainwrightReiterated RatingBuy$50.00
12/9/2021Leerink PartnersReiterated RatingBuy$26.00
11/15/2021HC WainwrightReiterated RatingBuy$49.00
9/2/2021HC WainwrightReiterated RatingBuy$50.00
8/9/2021HC WainwrightReiterated RatingBuy
8/8/2021Leerink PartnersReiterated RatingBuy$26.00
7/23/2021Jefferies Financial GroupInitiated CoverageBuy$32.00
6/15/2021Piper SandlerInitiated CoverageOverweight
4/21/2021HC WainwrightInitiated CoverageBuy
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 7 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Aclaris Therapeutics logo
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Read More

Today's Range

Now: $3.01
Low: $2.72
High: $3.08

50 Day Range

MA: $2.29
Low: $1.81
High: $3.01

52 Week Range

Now: $3.01
Low: $1.05
High: $4.03

Volume

1,616,426 shs

Average Volume

1,181,652 shs

Market Capitalization

$326.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Aclaris Therapeutics?

The following equities research analysts have issued reports on Aclaris Therapeutics in the last twelve months: Cantor Fitzgerald, HC Wainwright, Piper Sandler, Scotiabank, Wall Street Zen, Wedbush, and Weiss Ratings.
View the latest analyst ratings for ACRS.

What is the current price target for Aclaris Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Aclaris Therapeutics in the last year. Their average twelve-month price target is $9.75, suggesting a possible upside of 223.9%. HC Wainwright has the highest price target set, predicting ACRS will reach $16.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $6.00 for Aclaris Therapeutics in the next year.
View the latest price targets for ACRS.

What is the current consensus analyst rating for Aclaris Therapeutics?

Aclaris Therapeutics currently has 1 sell rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ACRS.

What other companies compete with Aclaris Therapeutics?

Other companies that are similar to Aclaris Therapeutics include Palvella Therapeutics, AbCellera Biologics, Phathom Pharmaceuticals, Biohaven and Kura Oncology. Learn More about companies similar to Aclaris Therapeutics.

How do I contact Aclaris Therapeutics' investor relations team?

Aclaris Therapeutics' physical mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company's listed phone number is (484) 324-7933 and its investor relations email address is [email protected]. The official website for Aclaris Therapeutics is www.aclaristx.com. Learn More about contacing Aclaris Therapeutics investor relations.